Project Grant HT94252310572
Award Date 9/15/23
Completion Date 9/14/27
Dollars Obligated $3.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
MIDDLE CITY WEST, PA 19103, USA
Similar Awards
- The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
- The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
- The Baylor College of Medicine will use a $1.6 million Project Grant from the Defense Health Agency to research germline variants and population-wide breast cancer risk. The grant was awarded on February 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through basic, applied, and advanced biomedical research, this project aims to transform healthcare for service members and the public by investigating medical solutions for the battlefield and developing...
- This Defense Health Agency (DHA) Project Grant award for $4,509,475.00, granted on Sep 15, 2023 under the Military Medical Research and Development program (CFDA 12.420), supports a 4-year research project titled "Optimizing a Surveillance Strategy to Tackle Breast Cancer Dormancy and Minimal Residual Disease" to be conducted by the Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The objective of this research is...
- The Defense Health Agency awarded a $1,598,801 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a Phase 1B study of the BCL-XL degrader DT2216 combined with paclitaxel in recurrent platinum-resistant ovarian cancer. This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members and the public. The study aims to investigate the efficacy of...
- The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
- The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...
- The Defense Health Agency awarded a $1,204,746 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Old Dominion University Research Foundation (Odurf) for the project "Early Detection of Cancer Disparity and Treatment Resistance in TNBC". The grant, with a performance period from September 1, 2024 to January 31, 2027, will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the...
- This Defense Health Agency Project Grant award of $1,204,899 to Duke University, with a period of performance from January 1, 2024 to December 31, 2027, supports targeted vaccination research to treat and prevent endocrine-resistant ER+ breast cancer. The project aims to develop new treatments by targeting common resistance genes and neoepitope mutations. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports...